Sumitomo Pharma reported double-digit revenue growth in Q1FY25, driven by North America. Operating loss narrowed. Net profit stood at ¥16B in Q1FY25. The company is expected to revise FY25 guidance.
What is covered in the Full Insight:
Introduction
Q1FY25 Financial Performance
Key Products Overview
Cost Management and Structural Reforms
Future Outlook and Catalysts
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.